Guest guest Posted December 28, 2001 Report Share Posted December 28, 2001 Thanks for your post. In the very nicest and sincerest way possible, I would like to ask which rock your " friend " has been living under? I am sure Devin could send him reams but just to see what an amateur could come up with on the first shot, I typed in " bromelain " and got lots of clinical evidence: Cell Mol Life Sci 2001 Aug;58(9):1234-45 Related Articles, Books, LinkOut Bromelain: biochemistry, pharmacology and medical use. Maurer HR. Department of Biochemistry, Molecular Biology and Biotechnology, Institute of Pharmacy, Freie Universitat Berlin, Germany. hrmaurer@... Bromelain is a crude extract from the pineapple that contains, among other components, various closely related proteinases, demonstrating, in vitro and in vivo, antiedematous, antiinflammatory, antithrombotic and fibrinolytic activities. The active factors involved are biochemically characterized only in part. Due to its efficacy after oral administration, its safety and lack of undesired side effects, bromelain has earned growing acceptance and compliance among patients as a phytotherapeutical drug. A wide range of therapeutic benefits has been claimed for bromelain, such as reversible inhibition of platelet aggregation, angina pectoris, bronchitis, sinusitis, surgical traumas, thrombophlebitis, pyelonephritis and enhanced absorption of drugs, particularly of antibiotics. Biochemical experiments indicate that these pharmacological properties depend on the proteolytic activity only partly, suggesting the presence of nonprotein factors in bromelain. Recent results from preclinical and pharmacological studies recommend bromelain as an orally given drug for complementary tumor therapy: bromelain acts as an immunomodulator by raising the impaired immunocytotoxicity of monocytes against tumor cells from patients and by inducing the production of distinct cytokines such as tumor necrosis factor-a, interleukin (Il)-1beta, Il-6, and Il-8. In a recent clinical study with mammary tumor patients, these findings could be partially confirmed. Especially promising are reports on animal experiments claiming an antimetastatic efficacy and inhibition of metastasis-associated platelet aggregation as well as inhibition of growth and invasiveness of tumor cells. Apparently, the antiinvasive activity does not depend on the proteolytic activity. This is also true for bromelain effects on the modulation of immune functions, its potential to eliminate burn debris and to accelerate wound healing. Whether bromelain will gain wide acceptance as a drug that inhibits platelet aggregation, is antimetastatic and facilitates skin debridement, among other indications, will be determined by further clinical trials. The claim that bromelain cannot be effective after oral administration is definitely refuted at this time. Publication Types: Review Review, Academic PMID: 11577981 [PubMed - indexed for MEDLINE] --------------------------------------------------------------------- Here is one effective with cancer treatment. There are tons of articles on cancer: Cancer Chemother Pharmacol 2001 Jul;47 Suppl:S4-9 Related Articles, LinkOut, Books Modulation of growth factor binding properties of alpha2- macroglobulin by enzyme therapy. Lauer D, Muller R, Cott C, Otto A, Naumann M, Birkenmeier G. Institute of Biochemistry, University of Leipzig, Germany. PURPOSE: To investigate the binding of transforming growth factor- beta (TGF-beta) to human alpha2-macroglobulin upon oral treatment of patients with proteases. METHODS: Volunteers were given a cocktail of active proteinases (Phlogenzym) composed of trypsin, bromelain and the additive rutoside orally over a period of 7 days at low dose followed by a bolus application. Before and after medication plasma was immediately withdrawn and binding of 125I-TGF-beta to the proteinase inhibitor alpha2-macroglobulin was determined by electrophoresis and gamma-counting. Cell culture experiments were performed to study the effect of transformed alpha2-macroglobulin on TGF-beta-stimulated proliferation of skin fibroblasts. RESULTS: Ingestion of proteinases was found to trigger the formation of intermediate forms of alpha2-macroglobulin displaying high affinity to TGF-beta. Maximum binding of TGF-beta was observed 1-2 h after bolus ingestion, and steadily levelled off with time. In vitro experiments demonstrated that complex formation of diverse proteinases (trypsin, alpha-chymotrypsin, bromelain and plasmin) with alpha2-macroglobulin conferred binding of 125I-TGF-beta, alpha2- Macroglobulin transformed by methylamine or proteinases was found to abolish the TGF-beta effect on fibroblasts in cell culture. CONCLUSIONS: Intestinal absorption of proteinases triggers the formation of TGF-beta binding species of alpha2-macroglobulin in blood. Mediated by this process high concentrations of TGF-beta might be reduced via enhanced clearance of alpha2-macroglobulin-TGF- beta complexes. Thus, proteinase therapy may have beneficial effects in treatment of fibrosis and certain cancers accompanied by excessively high TGF-beta concentrations. PMID: 11561872 [PubMed - indexed for MEDLINE] -------------------- Bromelain helps immune systems: Cell Immunol 2001 May 25;210(1):5-10 Related Articles, LinkOut, Books Bromelain activates murine macrophages and natural killer cells in vitro. Eur J Med Res 2001 May 29;6(5):193-200 Related Articles, Books Bromelain is an accelerator of phagocytosis, respiratory burst and Killing of Candida albicans by human granulocytes and monocytes. ------ How about helping arthritis: Clin Exp Rheumatol 2001 May-Jun;19(3):303-9 Related Articles, Books, LinkOut Inhibitory effect of enzyme therapy and combination therapy with cyclosporin A on collagen-induced arthritis. ---------------- How about compared to NSAIDS Arzneimittelforschung 2000 Aug;50(8):728-38 Related Articles, Books [Comparative epidemiological study in patients with rheumatic diseases illustrated in a example of a treatment with non-steroidal anti- inflammatory drugs versus an oral enzyme combination preparation] [Article in German] Wittenborg A, Bock PR, Hanisch J, Saller R, Schneider B. -------------------- Don't forget colitis: Ann Intern Med 2000 Apr 18;132(8):680 Related Articles, LinkOut, Books Use of bromelain for mild ulcerative colitis. PMID: 10766699 ---------------- Acta Chir Orthop Traumatol Cech 2001;68(1):45-9 Related Articles, Books [Article in Czech] Kamenicek V, Holan P, Franek P. CONCLUSION: The authors verified that systemic enzyme therapy could influence significantly the results of traumatological surgery. Simple administration per os, efficient oedema reduction and thus accelerated healing, antiophlogistic and analgesic effect--all these advantages justify the application of this therapeutic method what can be recommended as a part of the complex treatment in traumatology with both conservative and surgical approaches. --------------------- J Assoc Physicians India 2001 Jun;49:617-21 Related Articles, Books Efficacy and tolerability of oral enzyme therapy as compared to diclofenac in active osteoarthrosis of knee joint: an open randomized controlled clinical trial. CONCLUSION: Phlogenzym is as efficacious and well tolerated as diclofenac sodium in the management of active osteoarthrosis over three weeks of treatment. PMID: 11584936 ------------------- Enzymes are a very budding therapy for HIV patients: Aliment Pharmacol Ther 2001 Oct;15(10):1619-25 Related Articles, LinkOut, Books Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients. CONCLUSIONS: This pilot, open-label study showed that pancreatic enzyme supplementation therapy is highly effective in reducing faecal fat loss in human immunodeficiency virus-infected patients with nutrient malabsorption. Further double-blind studies must be undertaken to verify these results and, if they are confirmed, pancreatic enzymes can be added to our weapons in the fight against human immunodeficiency virus-associated nutrient malabsorption. PMID: 11564002 ---------------- For amylase: J Trop Pediatr 1998 Feb;44(1):4-9 Related Articles, Books Adding alpha-amylase to weaning food to increase dietary intake in children. A randomized controlled trial. den Besten L, Glatthaar II, Ijsselmuiden CB. Department of Human Nutrition, Faculty of Medicine, Medical University of Southern Africa, Medunsa, South Africa. The addition of alpha-amylase to a food supplement for weaning-age children was proposed as an alternative to traditionally prepared Amylase-Rich Foods (ARF) for reducing the dietary bulk of weaning diets. In a self-controlled clinical trial including 30 healthy children, aged 10-24 months, the effect of the addition of alpha- amylase and extra cereal to a diet including three meals, was determined in terms of dietary intake. A mean increased intake of 23.8 per cent in energy and 10.4 per cent in protein was found. The addition of commercial alpha-amylase to maize-based weaning foods is a useful method of increasing the nutritional value of weaning diets. Publication Types: Clinical Trial Randomized Controlled Trial PMID: 9538598 Sorry, there were so many I just didn't even get to entercolitis, Gaucher disease, other cancers, lipases, allergies, pacreatitis, Crohn's disease, or celiac (remember the amylase) for starters. If your " friend " has a particular condition or enzyme claim he would like some information on, I will be happy to look for it. But it would help if he could narrow the search because there are hundreds of references to go through. . Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.